Skip to main content

Advertisement

Log in

Efficacy and safety of orally administered pilocarpine hydrochloride for patients with juvenile-onset Sjögren’s syndrome

  • Original Article
  • Published:
Modern Rheumatology

Abstract

The number of patients with juvenile-onset Sjögren’s syndrome (SS) has recently increased. However, there is no drug that is safe and effective for the xerostomia that occurs in patients of this age group. We evaluated the efficacy and safety of orally administered pilocarpine hydrochloride for juvenile-onset SS patients. Five female patients, aged from 9 to 16 years, received 5–10 mg/day for 4 weeks. On days 1 and 28, salivary production was measured by the Saxon test, and patients completed subjective self-evaluations of xerostomia symptoms and were asked about changes in water intake and overall improvement of dry mouth on day 28. After 4 weeks of pilocarpine administration, salivary production increased significantly in all patients, and overall status was assessed as “improved” in all patients. One patient had excessive sweating. No serious adverse events or laboratory examination abnormalities correlated with pilocarpine administration were found. In conclusion, the results of this study suggest that orally administered pilocarpine is safe and effective for treating xerostomia in juvenile-onset SS patients. This is the first report of the efficacy of pilocarpine for juvenile SS patients; further evaluations are needed to confirm our result.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Tomiita M, Saito K, Kohno Y, Shimojo N, Fujikawa S, Niimi H. The clinical features of Sjögren’s syndrome in Japanese children. Acta Paediatr Jpn. 1997;39:268–72.

    CAS  PubMed  Google Scholar 

  2. Cimaz R, Casadei A, Rose C, Bartunkova J, Sediva A, Falcini F, et al. Primary Sjögren syndrome in paediatric age: a multicentre survey. Eur J Pediatr. 2003;162:661–5.

    Article  PubMed  Google Scholar 

  3. Singer NG, Tomaowa-Soltys I, Lowe R. Sjögren’s syndrome in childhood. Curr Rheumatol Rep. 2008;10:147–55.

    Article  PubMed  Google Scholar 

  4. Fujibayashi T, Sugai S, Miyasaka N, Hayashi Y, Tsubota K. Revised Japanese criteria for Sjögren’s syndrome (1999): availability and validity. Mod Rheumatol. 2004;14:425–34.

    Article  Google Scholar 

  5. Taylor P. Cholinergic agonists. In: Gilman AG, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 2004. p. 122–30.

    Google Scholar 

  6. Naito Y, Matsumoto I, Wakamatsu E, et al. Muscarinic acetylcholine receptor autoantibodies in patients with Sjögren’s syndrome. Ann Rheum Dis. 2005;64:510–1.

    Article  CAS  PubMed  Google Scholar 

  7. Nakamura Y, Wakamatsu E, Matsumoto I, et al. High prevalence of autoantibodies to muscarinic-3 acetylcholine receptor in patients with juvenile-onset Sjögren syndrome. Ann Rheum Dis. 2008;67:136–7.

    Article  CAS  PubMed  Google Scholar 

  8. Jorkjend L, Bergenholtz A, Johansson AK, et al. Effect of pilocarpine on impaired salivary secretion in patients with Sjögren’s syndrome. Swed Dent J. 2008;32:49–56.

    PubMed  Google Scholar 

  9. Rosas J, Ramos-Casals M, Ena J, et al. Usefulness of basal and pilocarpine-stimulated salivary flow in primary Sjögren’s syndrome. Correlation with clinical, immunological and histological features. Rheumatology. 2002;41:670–5.

    Article  CAS  PubMed  Google Scholar 

  10. Peluso G, De Santis M, Inzitari R, et al. Proteomic study of salivary peptides and proteins in patients with Sjögren’s syndrome before and after pilocarpine treatment. Arthritis Rheum. 2007;56:2216–22.

    Article  CAS  PubMed  Google Scholar 

  11. Papas AS, Sherrer YS, Charney M, et al. Successful treatment of dry mouth and dry eye symptoms in Sjögren’s syndrome patients with oral pilocarpine: a randomized, placebo-controlled, dose-adjustment study. J Clin Rheumatol. 2004;10:169–77.

    Article  PubMed  Google Scholar 

  12. Kuar A, Singla V, Khokhar S, et al. Efficacy of oral pilocarpine in patients with Sjögren’s syndrome. Indian J Rheumatol. 2006;1:93–8.

    Article  Google Scholar 

  13. Sugai S, Koike T, Miyasaka N, et al. Dose-finding study of oral pilocarpine for the treatment of xerostomia associated with Sjögren’s syndrome. Jpn Pharmacol Ther. 2007;35:s141–53.

    Google Scholar 

  14. Konno A, Nishio M, Origasa H. Oral pilocarpine for radiation-induced xerostomia: a randomized, double-blind, placebo-controlled trial. Jpn Pharmacol Ther. 2007;35:s131–9.

    Google Scholar 

Download references

Conflict of interest statement

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Minako Tomiita.

About this article

Cite this article

Tomiita, M., Takei, S., Kuwada, N. et al. Efficacy and safety of orally administered pilocarpine hydrochloride for patients with juvenile-onset Sjögren’s syndrome. Mod Rheumatol 20, 486–490 (2010). https://doi.org/10.1007/s10165-010-0313-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10165-010-0313-7

Keywords

Navigation